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Purpose: Limited evidence is available on whether the white blood cell (WBC) count is 
a predictor of type 2 diabetes mellitus (T2DM) in non-obese individuals. This study aimed to 
determine whether WBC count could be used as an indicator for the prediction of incident 
T2DM among non-obese individuals using a large, community-based Korean cohort that was 
observed over 10 years.
Patients and methods: A total of 4211 non-obese adults without diabetes aged 40–69 
years were selected from the Korean Genome and Epidemiology Study. The participants 
were divided into four groups according to WBC count quartiles. We prospectively assessed 
the hazard ratios (HRs) with 95% confidence intervals (CIs) for incident T2DM, based on the 
American Diabetes Association criteria, using multivariate Cox proportional hazards regres-
sion models over 10 years after the baseline survey.
Results: During the follow-up period, 592 (14.1%) participants had newly developed 
T2DM. The higher quartile of WBC count groups showed significantly higher cumulative 
T2DM incidence over 10 years after the baseline survey (log-rank test, P < 0.001). Compared 
with the HRs for individuals in the referent lowest quartile, the HR (95% CI) for incident 
T2DM in individuals in the highest quartile was 1.55 (1.10–2.18) after adjusting for 
confounding variables.
Conclusion: A higher WBC count predicts future incident T2DM among community- 
dwelling non-obese Korean adults. This study suggests that WBC count could facilitate the 
prediction of non-obese individuals susceptible to T2DM.
Keywords: white blood cell count, type 2 diabetes mellitus, chronic low-grade 
inflammation, non-obese adults
Introduction
Type 2 diabetes mellitus (T2DM) is characterized by relative insulin deficiency caused 
by insulin resistance in target organs and pancreatic β-cell dysfunction.1 Worldwide, it 
is a challenging public health problem because of its high prevalence and concomitant 
risks of various complications, and it is a major leading cause of disability and death in 
adults globally.2,3 In addition, individuals with T2DM, on an average, have approxi-
mately 2.3 times higher medical expenditures than those without T2DM.4 The global 
prevalence of T2DM increased from 4.7% in 1980 to 9.3% in 2019, and is estimated to 
rise to 10.2% (578 million) by 2030.5,6 Similarly, in South Korea, the prevalence of 
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T2DM has rapidly increased during the past several decades 
from 8.6% in 2001 to 14.4% in 2016.7,8 Furthermore, T2DM 
was the sixth leading cause of death in South Korea in 2018.9
Although obesity has long been considered a major risk 
factor for T2DM, susceptibility to T2DM has been 
reported to have heterogeneous features according to eth-
nicity and cultural subgroups.10 Specifically, Asians 
develop T2DM at a lower body-mass index (BMI) when 
compared with Caucasians, and the risk of T2DM starts at 
a lower BMI for Asians than for the Western 
populations.11,12 Indeed, the proportion of non-obese indi-
viduals among all T2DM patients was 52.6% for men and 
47.9% for women in 2013 in Korea.8 Interestingly, the 
prevalence of obesity among Korean women has 
decreased gradually from around 2000,13,14 whereas the 
incidence of T2DM has increased steadily over the last 
decade.15 Thus, early identification of individuals at high 
risk of T2DM in non-obese adults is considered important 
from a public health perspective.
Insulin resistance and T2DM are closely related to 
chronic low-grade inflammation.16,17 Inflammation mar-
kers, such as the white blood cell (WBC) count, high- 
sensitivity C-reactive protein (hsCRP), and interleukin-6, 
are known to be associated with metabolic syndrome and 
T2DM.18–20 Furthermore, several studies have revealed 
that WBC count, which is commonly measured in routine 
laboratory examination panels, is related to insulin resis-
tance and predicts the development of T2DM.21–24 In 
particular, it was reported that WBC count could be used 
as an indicator for the prediction of T2DM incidence 
among obese individuals.25 However, few prospective 
cohort studies have examined the relationship between 
WBC count and incident T2DM among non-obese indivi-
duals. Thus, this study aimed to determine whether WBC 
count could be used as an indicator for the prediction of 
incident T2DM among non-obese individuals using 
a large, community-based Korean cohort that was 
observed over 10 years.
Patients and Methods
Study Overview and Study Participants
Participants were recruited from the Korea Association 
Resource study, which is a part of the Korean Genome 
and Epidemiology Study (KoGES), a population-based 
prospective cohort study conducted by the Korean 
Centers for Disease Control and Prevention. Detailed 
information about the study participants and methodology 
of KoGES has been described in a previous study.26 In the 
KoGES study, adults aged 40–69 years in Ansung (a rural 
area) and Ansan (an urban area) were enrolled to investi-
gate the prevalence of and risk factors for chronic diseases 
in Korea.
A total of 8840 adults aged 40–69 years were included in 
the baseline study conducted from 2001 to 2002. Baseline 
examinations were conducted in 2001–2002, and follow-up 
examinations continued biennially until 2012. Among the 
8840 participants in the baseline survey, we excluded 3062 
obese participants. We defined obese participants as those 
individuals with a BMI ≥ 25 kg/m2 based on the Asia-Pacific 
regional guidelines of the World Health Organization and 
International Obesity Task Force.27 We also excluded 613 
participants because they either were previously diagnosed 
with T2DM or met the diagnostic criteria for T2DM in the 
baseline survey. Of the remaining participants, we also 
excluded 464 participants with a WBC count <4000 cells/ 
mL or >10,000 cells/μL to rule out the possibility of an 
inflammatory disorder, infection, or bone marrow suppres-
sive illness. During the 10-year follow-up period, 490 parti-
cipants were further excluded due to loss to follow-up and 
incomplete follow-up data. After these exclusions, 4211 par-
ticipants were included in the final analysis. All individuals 
voluntarily participated in the study, and informed consent 
was obtained from all participants. This study was approved 
by the Institutional Review Board of Yonsei University 
Yongin Severance Hospital (Institutional Review Board 
number 9–2016-0013). In addition, this study complied 
with the ethical principles underlined in the Declaration of 
Helsinki.
Clinical and Biochemical Measurement
The study data included the medical history and socio-
demographic information recorded by a self-administered 
questionnaire, anthropometric measurements, and labora-
tory biochemical measurements. All study participants 
were also requested to answer a health-related behavior 
questionnaire that included topics related to smoking and 
alcohol consumption. In the present study, current smokers 
were individuals who smoked ≥ 100 cigarettes in their 
lifetime and currently smoked at the time of the study, 
and an alcohol drinker was defined as an individual who 
consumed alcohol more than twice a week.
Participants’ body weight and height were measured to the 
nearest 0.1 kg and 0.1 cm, respectively, with participants 
wearing light indoor clothing and no shoes. The BMI was 
calculated as weight (kg) divided by the square of the height 
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(m2). The waist circumference was measured to the nearest 
0.1 cm at the midpoint between the lower border of the rib cage 
and the iliac crest at the end stage of normal expiration. Systolic 
and diastolic blood pressures were measured twice using 
a standard mercury sphygmomanometer (Baumanometer 
Standby; W.A. Baum, New York, NY, USA).
Blood samples were obtained in the morning after an 
overnight fast. WBC count was determined using 
a hematological analyzer (ADVIA 120; Siemens, 
Tarrytown, NY, USA). Glucose, total cholesterol, triglycer-
ides, and high-density lipoprotein cholesterol levels were 
measured using an automatic analyzer (ADVIA 1650; 
Siemens, Tarrytown, NY, USA). Glycated hemoglobin A1c 
(HbA1c) levels were measured using high-performance 
liquid chromatography (Variant II; BioRad Laboratories, 
Hercules, CA, USA). Insulin levels were determined using 
a radioimmunoassay kit (LINCO Research, St. Charles, MO, 
USA) with intra-assay and inter-assay coefficients of varia-
tion ranging from 2.1% to 8.3%. The Denka Seiken (Tokyo, 
Japan) assay, which has been validated against the Dade 
Behring method, was used to measure hsCRP level. The 
homeostatic model assessment of insulin resistance (HOMA- 
IR) was determined using the following equation: fasting 
glucose (mg/dL) × fasting insulin (μIU/mL)/405. T2DM 
was defined as the presence of one or more of the following 
conditions: fasting glucose level ≥ 126 mg/dL, HbA1c ≥ 
6.5%, and 2-hour plasma glucose level of oral glucose toler-
ance test ≥ 200 mg/dL, based on the American Diabetes 
Association,28 or ongoing treatment with oral antidiabetic 
medications or insulin therapy. Prediabetes was defined as 
one or more of the following conditions: fasting glucose level 
between 100–125 mg/dL, HbA1c level between 5.7–6.4%, 
and 2-hour plasma glucose level between 140–199 mg/dL in 
the oral glucose tolerance test.
Statistical Analyses
WBC count quartiles were categorized as follows: Q1, ≤ 
5200; Q2, 5300–6100; Q3, 6200–7300; and Q4, ≥ 7400 
cells/μL. The baseline characteristics of the study popula-
tion according to WBC count quartiles were compared 
using one-way analysis of variance (ANOVA) or the 
Kruskal-Wallis test for continuous variables according to 
the normality of distributions. The chi-squared test was 
used to compare the categorical variables. Continuous data 
are presented as means ± standard deviation or medians 
(interquartile range). Categorical data are presented as 
frequencies.
The hazard ratios (HRs) with 95% confidence intervals 
(CIs) for incident T2DM were calculated using multivariate 
Cox proportional hazards regression models after adjusting 
for potentially confounding variables. The lowest quartile, 
Q1, was set as the reference group for the WBC count. The 
cumulative incidence of T2DM was determined using the 
Kaplan-Meier curve. Log-rank tests were conducted to 
determine the differences in the cumulative incidence of 
T2DM among the groups. The Contal and O’Quigley 
method was used to determine the optimal cut-off point for 
the WBC count with maximized log-rank statistics.
All analyses were conducted using SAS statistical soft-
ware (version 9.4; SAS Institute Inc., Cary, NC, USA). 
A p-value < 0.05 was considered as significant.
Results
Table 1 presents the baseline characteristics of 4211 parti-
cipants without T2DM at baseline according to their WBC 
count quartiles. The mean values of a few cardiometabolic 
variables, such as blood pressure, triglycerides, and hsCRP 
levels, tended to increase proportionally with the WBC 
count quartiles. However, there was no significant differ-
ence in the median values of insulin and HOMA-IR 
among the WBC count quartiles.
Table 2 shows the incidence of T2DM during the 10- 
year follow-up period, during which the incidence rates 
were calculated biennially. A total of 592 individuals 
(14.1%, 592 of 4211) developed T2DM during the 10- 
year follow-up period. The incidence rate per 2 years 
ranged from 1.2–5.9.
The cumulative incidence of T2DM according to WBC 
count quartiles is illustrated in Figure 1 as a Kaplan–Meier 
curve. The higher quartile of WBC count groups showed 
significantly higher cumulative T2DM incidence over 10 
years after the baseline survey (log-rank test, P < 0.001).
Table 3 shows the results of the multivariate Cox 
proportional hazards regression analysis for predicting 
T2DM according to WBC count quartiles. In Model 1, 
we calculated the hazard ratios after adjusting for age 
and sex. In model 2, we adjusted for additional potential 
confounding variables, including smoking, alcohol con-
sumption, waist circumference, systolic blood pressure, 
fasting plasma glucose, and family history of T2DM. In 
model 3, we investigated the association between WBC 
count and incident T2DM by additional adjustment for 
HOMA-IR, hsCRP levels, and prediabetes. Compared to 
the reference first quartile, the HRs (95% CIs) of the 
incidence of T2DM in the second, third, and fourth 
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quartiles increased in a dose–response manner among all 
models. Compared to the lowest quartiles, the HRs (95% 
CIs) of the incidence of T2DM in the highest WBC count 
quartile were 2.04 (1.48–2.81) in the unadjusted model, 
1.96 (1.42–2.70) in model 1, 1.71 (1.22–2.39) in model 2, 
and 1.55 (1.10–2.18) in model 3.
Supplementary Figure S1 suggests the potential of 
a clinically meaningful WBC count threshold at ≥ 6600 
cells/μL.
Discussion
In this large-scale prospective community-based Korean 
cohort that was observed over 10 years, we found that 
a higher WBC count was positively and independently 
associated with incident T2DM among community- 
dwelling non-obese Korean adults. This association 
between WBC count and incidence of T2DM was inde-
pendent of insulin resistance, even after adjusting for 
HOMA-IR. Our findings are consistent with the results 
of previous studies showing that an increased WBC 
count is positively associated with incident T2DM.21–24 
Moreover, our results suggest that WBC count could be 
a useful marker for non-obese adults susceptible to T2DM, 
independent of insulin resistance. Few previous studies 
have examined the relationship between WBC count and 
the incidence of T2DM among non-obese adults. We 
believe that this is the first large population-based cohort 
study to reveal a positive relationship between WBC count 
and the incidence of T2DM regardless of baseline insulin 
resistance in a non-obese population. Thus, our results 
expand upon earlier findings regarding the association 
between WBC count and incident T2DM. Smoking, 
waist circumference, and hsCRP levels tended to increase 
with WBC count quartiles, and they could influence the 
relationship between WBC count and incident T2DM. We 
included these factors as confounding variables in Cox 
regression analyses to control for potential confounding. 
An interaction test was also performed, and it identified 
that the influence of the WBC count is not dependent on 
Figure 1 Cumulative incidence of type 2 diabetes according to WBC count quartiles in the non-obese population.











2003–2004 2 years 3973 47 1.2
2005–2006 4 years 3559 83 2.3
2007–2008 6 years 3161 109 3.5
2009–2010 8 years 3188 188 5.9
2011–2012 10 years 2994 165 5.5
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each variable. Further studies are warranted to elucidate 
the relationship between WBC count and incident T2DM 
among non-obese adults by matching these factors, or 
subgroup analysis, in more participants.
Chronic low-grade inflammation is known to be 
involved in the pathogenesis of obesity-related 
T2DM.16,29 Adipose tissue is generally considered as the 
major and earliest trigger of chronic low-grade inflamma-
tion in obesity-related T2DM, with prominent infiltration 
of lymphocytes, macrophages, and other immune cells into 
this tissue.30–33 These cells are essential for the production 
of pro-inflammatory cytokines, which function in an auto-
crine and paracrine fashion to induce insulin resistance by 
inhibiting insulin signaling in peripheral tissues.34–36
Non-obese individuals with T2DM were also identified 
by an increase in pro-inflammatory cytokines, such as 
interleukin-8 and interleukin-18.37 Unlike obesity-related 
T2DM, dysfunctional adipocytes could not be considered 
as the major determinants of chronic low-grade inflamma-
tion, and over-nutrition could not be regarded as the only 
trigger of chronic low-grade inflammation in the case of 
non-obese individuals with T2DM. Other factors, such as 
pancreatic β-cell failure and alterations in gut microbiota 
composition, are also possible mechanisms of inflamma-
tion that are involved and can also be found in non-obese 
T2DM. It has been suggested that the “stressed” pancreatic 
β-cell may trigger local inflammation and alter the balance 
between pancreatic β-cell mass and function in 
Langerhans islets in individuals with a genetic predisposi-
tion, which leads to a decrease in both pancreatic β-cell 
number and function.38–41 Macrophages, interleukin-1β, 
and other immune cells are known to be involved in islet 
inflammation in T2DM.42–44 In addition, altered gut 
microbiota can directly influence immune cells in the gut 
and indirectly influence immune cells through microbial 
products, such as short-chain fatty acids, lipopolysacchar-
ides, and other metabolites, all of which can have an effect 
on insulin resistance.45–48 Short-chain fatty acids are 
believed to regulate gene expression of human monocytes 
and decrease chemokine production and inflammatory 
cytokine, whereas lipopolysaccharides can lead to subcli-
nical inflammation mediated by the induction of pro- 
inflammatory cytokines by immune cells.45,49
This study has several limitations that should be con-
sidered. First, only one measurement of WBC count was 
included in the analysis, and thus, it was not possible to 
determine whether an acute and brief episode of infection 
affected the findings observed in this study. In an attempt 
to minimize this limitation, participants with a WBC count 
≥ 10,000 cells/mL were excluded. Second, this study did 
not show the effect of sequential changes in the WBC 
count, since we only considered the baseline measure-
ments of the WBC count. Third, the KoGES did not 
duplicate the measurement of blood glucose levels, and 
T2DM diagnosis could not be confirmed by repeat testing. 
Fourth, this study did not exclude the presence of potential 
Table 3 Hazard Ratios and 95% Confidence Intervals for Incident Type 2 Diabetes According to WBC Count Quartiles
WBC Count Quartiles






Q4 (≥ 7400) 
(n = 1023)
New cases of diabetes, n 58 75 87 108
Mean follow-up, years 8.41 8.25 7.99 7.92
Person-years of 
follow-up
8463 8807 8905 8098
Unadjusted 1.00 1.28 (0.91–1.80) 1.48 (1.06–2.06) 2.04 (1.48–2.81)
Model 1 1.00 1.23 (0.87–1.73) 1.42 (1.02–1.98) 1.96 (1.42–2.70)
Model 2 1.00 1.27 (0.90–1.80) 1.45 (1.03–2.03) 1.71 (1.22–2.39)
Model 3 1.00 1.22 (0.96–1.72) 1.39 (0.99–1.95) 1.55 (1.10–2.18)
Notes: Model 1: adjusted for age and sex. Model 2: adjusted for age, sex, smoking, alcohol consumption, waist circumference, systolic blood pressure, fasting plasma 
glucose, and family history of type 2 diabetes. Model 3: adjusted for age, sex, smoking, alcohol consumption, waist circumference, systolic blood pressure, fasting plasma 
glucose, family history of type 2 diabetes, HOMA-IR, hsCRP, and prediabetes. 
Abbreviations: WBC, white blood cell; HOMA-IR, homeostatic model assessment of insulin resistance; hsCRP, high-sensitivity C-reactive protein.
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autoimmune or inflammatory disorders. Therefore, further 
studies that consider latent autoimmune diabetes in adults, 
autoimmune diseases, and inflammatory diseases are 
needed. Fifth, despite the large population size, this study 
was performed in a Korean population. Therefore, our 
results may not be generalizable to other racial/ethnic 
populations. Lastly, the study population may not repre-
sent the general Korean population, since the participants 
resided in a rural area and an urban area. Therefore, this 
study may have been subject to a selection bias. Despite 
these limitations, we believe that our findings would have 
clinical implications with regard to preventive public 
health strategies among non-obese individuals who may 
be at a high risk of developing T2DM.
Conclusion
In conclusion, a higher WBC count predicts future inci-
dent T2DM that is independent of other associated vari-
ables, including HOMA-IR, among community-dwelling 
non-obese Korean adults. In clinical practice, WBC count, 
which is inexpensive and commonly measured in routine 
laboratory examination panels, could facilitate the predic-
tion of non-obese individuals susceptible to T2DM.
Abbreviations
BMI, body mass index; HOMA-IR, homeostatic model 
assessment of insulin resistance; hsCRP, high-sensitivity 
C-reactive protein; T2DM, type 2 diabetes mellitus; WBC, 
white blood cell.
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